NMN for Post-COVID Fatigue: What the Evidence Actually Shows

By T Dinaiz · BSc Molecular Biology, MSc Biotechnology

Last reviewed 2026-04-28. NMN's evidence base, and Malaysian NPRA/JAKIM/price details, can change - confirm current status with primary sources and a registered doctor before acting.

What long COVID actually is in 2026

Long COVID - formally Post-Acute Sequelae of SARS-CoV-2 infection (PASC) - is a heterogeneous condition affecting an estimated 5-15 percent of people who had COVID-19, with fatigue, cognitive dysfunction, breathlessness, and post-exertional malaise (PEM) as the most reported symptoms.

Five years into the pandemic era, the working framework recognises long COVID as a syndrome with multiple overlapping subtypes rather than a single disease, and clinical management has moved away from a one-size approach.

For Malaysians, the impact has been visible. Public hospital outpatient post-COVID clinics opened across UMMC, HKL, Penang General and Sunway in 2022-2024, and many remain operational in 2026 for patients still managing symptoms years after their initial infection.

The Ministry of Health’s surveillance data, while imperfect, suggests tens of thousands of Malaysians experienced post-COVID symptoms lasting more than 12 weeks, with a smaller subset of severe cases unable to return to baseline function.

The condition is real, the suffering is real, and the science is moving - slowly and with caveats. Mainstream treatment remains symptomatic and supportive, with cardiac rehabilitation, graded exercise (where PEM allows), pacing, sleep restoration, and treatment of identifiable co-occurring conditions (orthostatic intolerance, mast cell activation, autonomic dysfunction, anxiety/depression) forming the backbone.

Supplements, including NMN, occupy a discretionary supportive role at the edges of this picture - and that is the honest framing for any Malaysian patient considering them.

The NAD+ depletion mechanism

The biological case for NAD+ supplementation in long COVID rests on a specific and well-described mechanism: SARS-CoV-2 infection triggers PARP activation. PARPs (poly ADP-ribose polymerases) are NAD+-consuming enzymes that respond to viral RNA and the resulting cellular stress. PARP1 in particular can deplete cellular NAD+ pools rapidly during sustained viral inflammation.

When NAD+ falls, sirtuin activity falls. SIRT1, SIRT3 and SIRT6 - central regulators of mitochondrial function, metabolic health, and DNA repair - all rely on NAD+ as a substrate.

The downstream effects on mitochondria can be substantial: reduced ATP synthesis, altered fatty-acid oxidation, increased reactive oxygen species, and impaired clearance of damaged mitochondrial pools through mitophagy. The fatigue, exercise intolerance, and cognitive symptoms of long COVID overlap meaningfully with the symptom pattern of mitochondrial dysfunction in other contexts.

This is the mechanistic rationale for NAD+ precursor supplementation in post-COVID care. It is not, however, proof that NMN reverses long COVID symptoms in a clinically meaningful way. The mechanism predicts a possible benefit; the trials would need to demonstrate it.

What the evidence actually shows

At the last editorial review, the published clinical evidence for NMN specifically in long COVID populations is limited to small open-label studies and case series. Most cited work in the post-viral fatigue space involves nicotinamide riboside (NR), where modest signals have been reported in pilot trials.

NMN trials in long COVID are in earlier stages - registered, recruiting in some cases, but not yet published as full randomised controlled trials with PEM-validated populations.

The tangentially relevant evidence base includes:

Igarashi 2022 in older men, demonstrating safety and modest physical-performance benefit at 250mg/day over 12 weeks. This was not a long COVID trial, but it establishes the safety profile and dose-response context.

Kim 2022 showing modest improvements in sleep quality, fatigue, and physical-performance measures in older adults. Sleep disturbance is a common long COVID feature, but this is indirect support only; it is not a long COVID treatment trial.

Animal models of viral infection and NAD+ depletion showing that NMN supplementation can partially restore NAD+ levels and downstream mitochondrial function. The translation gap from mouse models to human long COVID is wide, but the directionality of effect is consistent.

The honest summary: there is a plausible mechanism, supportive small-trial data, and an absence of large RCTs proving clinical benefit. A patient considering NMN for post-COVID fatigue should understand that they are operating on mechanism plus mechanism-aligned safety data, not on proven efficacy.

A cautious Malaysian discussion checklist

For a Malaysian patient with documented long COVID symptoms, the order of operations matters:

1. Medical evaluation first. See a GP or attend a post-COVID clinic. Rule out anaemia, hypothyroidism, cardiac sequelae, sleep apnoea, vitamin D deficiency, B12 deficiency, and other treatable causes of fatigue. Check for orthostatic intolerance with active stand testing if dizziness is part of the picture.

2. Foundational interventions. Pacing (the fundamental skill - staying within the activity envelope that does not provoke PEM), graded sleep restoration (regular bed and wake times, sleep hygiene, treating sleep apnoea where present), and where PEM is absent, slowly graded physical reconditioning under physiotherapy guidance.

3. Address co-occurring conditions. Mast cell activation can be treated with H1/H2 antihistamines (loratadine, famotidine). Orthostatic intolerance can be managed with hydration, salt loading, compression, and where needed, midodrine or fludrocortisone. Anxiety/depression often co-exist and benefit from treatment.

4. NMN as discretionary support. Ask your doctor or pharmacist whether the published trial-dose context is relevant to your situation. If they agree it is worth a cautious trial, document the exact product, dose, timing, symptoms, and any other supplements instead of treating NMN as a fatigue regimen.

5. Monitor and adjust. Track 2-3 simple metrics weekly: a fatigue score (0-10 self-rated), a sleep score (hours and subjective quality), and a PEM indicator (any post-exertional crash and how long it lasted). Compare month-on-month. Improvements should be gradual; week-to-week changes are noisy.

6. Reassess before continuing. If no meaningful change appears across an agreed monitoring window, the supplement is unlikely to be contributing meaningful benefit for that individual. If you perceive benefit, review it with your clinician before continuing long term.

What not to do

Long COVID is a vulnerable population for supplement marketing. Common mistakes Malaysian patients make:

Stacking aggressively from day one. Adding NMN, NR, methylene blue, glutathione, NAD+ IV drips, and ten other supplements simultaneously makes attribution impossible and increases the risk of adverse interactions. Add one thing at a time, give it 8-12 weeks, evaluate, then consider the next addition.

Buying expensive NAD+ IV drips. NAD+ IV therapy in private clinics is heavily marketed for long COVID. The published evidence base for IV NAD+ in long COVID is even thinner than for oral NMN, and the cost (RM 800-2000 per session) is steep.

Oral NMN at 250mg/day is cheaper, evidence-aligned, and avoids the cannulation risk. We do not recommend IV NAD+ as a first-line approach in long COVID.

Ignoring pacing in pursuit of “doing something.” The most consistent harm in long COVID care comes from over-exertion and PEM. A patient who feels marginal benefit from NMN and uses that to push beyond their activity envelope can lose ground rapidly. The supplement does not increase exertion tolerance enough to override the pacing discipline.

Skipping medical evaluation. A Malaysian with persistent fatigue who self-prescribes NMN and never sees a doctor risks missing treatable conditions. The cost of a Klinik Kesihatan visit is RM 1; the cost of missing a thyroid abnormality or a cardiac complication is much higher.

Halal and Malaysian context

Standard halal verification applies. NMN itself is fermentation-derived and free of animal materials. Capsule shells should be HPMC for clean halal status; gelatin shells require additional verification of animal source. JAKIM-certified brands at the time of writing are limited; treat ambiguous cases as syubhah and verify on halal.gov.my.

For Muslim patients fasting during Ramadan while managing long COVID, ask your clinician how supplement timing should be handled around sahur/iftar, and ask a local religious authority if fasting validity matters to your decision.

For Malaysian patients still on regular hospital follow-up, mention NMN to your treating team. Some clinicians may be comfortable documenting it as a supplement question; others may advise against it given your clinical context.

Bottom line

Long COVID is real, multidimensional, and slow to resolve for some Malaysians. The interventions with the strongest evidence are pacing, sleep restoration, treating co-occurring conditions, and graded reconditioning where PEM allows. NMN is a supplement question to discuss after those foundations, not a treatment plan for post-COVID fatigue.

Order of operations: medical evaluation, foundational interventions, NMN as a discretionary add-on, monitoring at 8-12 weeks, decision at 6 months. The supplement is a small component of a larger recovery picture, and the recovery picture is what matters.